BRPI0510940A - 1-aza-biciclo-3.1.1-nonanos - Google Patents

1-aza-biciclo-3.1.1-nonanos

Info

Publication number
BRPI0510940A
BRPI0510940A BRPI0510940-0A BRPI0510940A BRPI0510940A BR PI0510940 A BRPI0510940 A BR PI0510940A BR PI0510940 A BRPI0510940 A BR PI0510940A BR PI0510940 A BRPI0510940 A BR PI0510940A
Authority
BR
Brazil
Prior art keywords
group
substituted
aza
unsubstituted
aryl
Prior art date
Application number
BRPI0510940-0A
Other languages
English (en)
Inventor
Dominik Feuerbach
Werner Mueller
Bernard Lucien Roy
Thomas J Troxler
Konstanze Hurth
Mathias Frederiksen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0510940A publication Critical patent/BRPI0510940A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1-AZA-BICICLO-3.3.1-NONANOS A invenção refere-se a derivados de 1-aza-bicicloalquila de fórmula (I); em que os substituintes são como definidos no relatório descritivo, ao processo para sua produção, seu uso como produtos farmacêuticos e a composições farmacêuticas compreendendo-os. Fórmula (I), em que A representa O ou N(R¬ 1¬); Y representa um grupo da fórmula ou em que a ligação esquerda é feita com o grupo A e a ligação direita é feita com o grupo R; R representa uma C~ 5~-C~ 10~arila substituída ou não-substituída, um hetero-C~ 5~-C~ 10~arila substituída ou não-substituída, um grupo N(R¬ 1¬)(R¬ 4¬), ou um grupo N(R¬ 2¬) (CHR¬ 3¬R¬ 4¬): R¬ 1¬ representa hidrogênio, C~ 1~-C~ 4~alquiia ou CF~ 3~; R¬ 2¬ representa hidrogênio, C~ 1~-C~ 4~alquila ou CF~ 3~; R¬ 3¬ representa hidrogênio, C~ 1~-C~ 4~alquila ou CF~ 3~; R¬ 4¬ representa um C~ 5~-C~ 10~arila substituída ou não-substituída ou um C~ 5~-C~ 10~ heteroarila substituída ou não-substituída; em forma de base livre ou em forma de sal de adição ácido.
BRPI0510940-0A 2004-06-18 2005-06-17 1-aza-biciclo-3.1.1-nonanos BRPI0510940A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58102004P 2004-06-18 2004-06-18
PCT/EP2005/006566 WO2005123732A1 (en) 2004-06-18 2005-06-17 1-aza-bicyclo[3.3.1]nonanes

Publications (1)

Publication Number Publication Date
BRPI0510940A true BRPI0510940A (pt) 2007-11-20

Family

ID=35045272

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510940-0A BRPI0510940A (pt) 2004-06-18 2005-06-17 1-aza-biciclo-3.1.1-nonanos

Country Status (32)

Country Link
US (3) US20070249657A1 (pt)
EP (2) EP2336129A1 (pt)
JP (1) JP4944772B2 (pt)
KR (3) KR101174173B1 (pt)
CN (1) CN1964968A (pt)
AR (1) AR049401A1 (pt)
AT (1) ATE506362T1 (pt)
AU (1) AU2005254689B2 (pt)
BR (1) BRPI0510940A (pt)
CA (1) CA2566155C (pt)
CY (1) CY1111528T1 (pt)
DE (1) DE602005027567D1 (pt)
DK (1) DK1761533T3 (pt)
EC (1) ECSP067053A (pt)
ES (1) ES2364971T3 (pt)
HR (1) HRP20110535T1 (pt)
IL (2) IL179611A (pt)
MA (1) MA28684B1 (pt)
MX (1) MXPA06014697A (pt)
MY (1) MY147262A (pt)
NO (1) NO20070339L (pt)
NZ (1) NZ551198A (pt)
PE (1) PE20060437A1 (pt)
PL (1) PL1761533T3 (pt)
PT (1) PT1761533E (pt)
RU (1) RU2445313C2 (pt)
SG (1) SG153834A1 (pt)
SI (1) SI1761533T1 (pt)
TN (1) TNSN06407A1 (pt)
TW (1) TWI370128B (pt)
WO (1) WO2005123732A1 (pt)
ZA (1) ZA200609255B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6262265A (ja) * 1985-09-13 1987-03-18 Hitachi Ltd 復水器自動検査補修システム
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
PE20060437A1 (es) * 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
CN102573842A (zh) * 2009-07-23 2012-07-11 诺瓦提斯公司 氮杂双环烷基衍生物或吡咯烷-2-酮衍生物的用途
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
CN103180321A (zh) 2010-09-23 2013-06-26 Abbvie公司 氮杂金刚烷衍生物的一水合物
KR20140003580A (ko) * 2011-01-27 2014-01-09 노파르티스 아게 니코틴성 아세틸콜린 수용체 알파 7 활성화제의 용도
WO2012127393A1 (en) 2011-03-18 2012-09-27 Novartis Ag COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE
JP6162705B2 (ja) 2011-10-20 2017-07-12 ノバルティス アーゲー アルファ７ニコチン性アセチルコリン受容体活性化剤による処置に対する応答性を予測するバイオマーカー
CA2872005A1 (en) * 2012-05-08 2013-11-14 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
US9458137B2 (en) * 2012-11-05 2016-10-04 Nantbioscience, Inc. Substituted indol-5-ol derivatives and their therapeutical applications
KR102043309B1 (ko) 2012-12-11 2019-11-11 노파르티스 아게 알파 7 니코틴성 아세틸콜린 수용체 활성화제 치료에 대한 반응성의 예측 바이오마커
CN105263492B (zh) * 2013-01-15 2018-04-10 诺华有限公司 α7烟碱型乙酰胆碱受体激动剂在治疗发作性睡病中的应用
US20150313884A1 (en) 2013-01-15 2015-11-05 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
EP2945633B1 (en) * 2013-01-15 2021-06-30 Novartis AG Use of alpha 7 nicotinic acetylcholine receptor agonists
BR112015016992A8 (pt) * 2013-01-15 2018-01-23 Novartis Ag uso de agonistas do receptor alfa 7 nicotínico de acetilcolina
JP7312749B2 (ja) 2017-08-04 2023-07-21 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングをモジュレートする方法および組成物
JP7551629B2 (ja) 2019-02-05 2024-09-17 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
WO2020163405A1 (en) 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
JP7603594B2 (ja) 2019-02-06 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
JP7603595B2 (ja) 2019-02-06 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB281309A (en) 1926-11-27 1928-03-29 Inventia Patent Verwert Ges Improvements in or relating to brushing machines having replaceable brush members
US3310553A (en) 1962-09-25 1967-03-21 Pfizer & Co C Alkylated thioxathenesulfonamides
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
BE759371A (fr) 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
DE2139107A1 (de) 1971-08-04 1973-02-15 Merck Patent Gmbh Heterocyclisch substituierte adenosinverbindungen
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
ZA848275B (en) 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
US4605652A (en) 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
ES2053451T3 (es) 1986-01-07 1994-08-01 Beecham Group Plc Un procedimiento para la preparacion de un compuesto que tiene propiedades farmacologicas utiles.
KR880007433A (ko) 1986-12-22 1988-08-27 메리 앤 터커 3-아릴옥시-3-치환된 프로판아민
EP0287356B1 (en) 1987-04-15 1996-01-24 Beecham Group Plc Bridgehead substituted azabicyclic derivatives
GB8718445D0 (en) * 1987-08-04 1987-09-09 Wyeth John & Brother Ltd Pyridyl-ethers
CA1307790C (en) 1987-08-04 1992-09-22 Ian Anthony Cliffe Ethers
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
DE3839385A1 (de) 1988-11-22 1990-05-23 Boehringer Ingelheim Kg Neue quinuclidine, ihre herstellung als arzneimittel und verfahren zu ihrer herstellung
GB8829079D0 (en) 1988-12-13 1989-01-25 Beecham Group Plc Novel compounds
CA2002182C (en) 1989-11-03 2000-06-13 Richard J. Wurtman Compositions for treating the premenstrual or late luteal phase syndrome and methods for their use
YU84791A (sh) 1990-05-19 1994-06-10 Boehringer Ingelheim Kg. Biciklicni 1-aza-cikloalkalni
DE4116582A1 (de) 1990-05-19 1991-11-21 Boehringer Ingelheim Kg Bicyclische 1-aza-cycloalkane
US5589477A (en) * 1990-08-31 1996-12-31 Nippon Shinyaku Company, Limited Pyrimidine derivatives and drugs
JP3087763B2 (ja) * 1990-11-30 2000-09-11 三井化学株式会社 新規な複素環式化合物およびそれを含有する医薬組成物
US5260303A (en) * 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
CA2105655A1 (en) 1991-03-08 1992-09-09 Kent Neuenschwander Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors
US5385912A (en) * 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
JPH05310732A (ja) 1992-03-12 1993-11-22 Mitsubishi Kasei Corp シンノリン−３−カルボン酸誘導体
JPH06508377A (ja) * 1992-04-10 1994-09-22 ゼネカ　リミテッド ヘテロ環式化合物
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
AU7394394A (en) 1992-10-13 1995-12-05 Rhone-Poulenc Rorer Pharmaceuticals Inc. 3-hydroxyquinuclidin-3-ylphenylquinolines as squalene synthase inhibitors
JPH06293768A (ja) 1993-02-12 1994-10-21 Sankyo Co Ltd イソオキサゾールオキシ誘導体
WO1994018201A1 (fr) 1993-02-12 1994-08-18 Sankyo Company, Limited Derive d'isoxazoleoxy
JP3235913B2 (ja) 1993-07-30 2001-12-04 エーザイ株式会社 アミノ安息香酸誘導体
US5998404A (en) 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
JPH11512443A (ja) 1995-09-22 1999-10-26 ノボ ノルディスク アクティーゼルスカブ 新規な置換アザ環式またはアザ二環式化合物
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
JP2002500652A (ja) 1997-05-30 2002-01-08 ニューロサーアチ・アクティーゼルスカブ スピロ−キヌクリジン誘導体、その製造方法及びその使用方法
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
ES2313900T3 (es) 1999-07-28 2009-03-16 The Board Of Trustees Of The Leland Stanford Junior University Nicotina en angiogenesis y vasculogenesis terapeutica.
SE9903760D0 (sv) 1999-10-18 1999-10-18 Astra Ab New compounds
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
WO2001066546A1 (en) 2000-03-09 2001-09-13 Mitsubishi Pharma Corporation Spiro compounds, process for preparing the same and use thereof as drugs
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
JP4616971B2 (ja) 2000-07-18 2011-01-19 田辺三菱製薬株式会社 １−アザビシクロアルカン化合物およびその医薬用途
US6479510B2 (en) 2000-08-18 2002-11-12 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6599916B2 (en) 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
GB0021885D0 (en) 2000-09-06 2000-10-18 Fujisawa Pharmaceutical Co New use
PE20021019A1 (es) 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
BR0213760A (pt) 2001-10-26 2004-10-19 Upjohn Co Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
DE10156719A1 (de) * 2001-11-19 2003-05-28 Bayer Ag Heteroarylcarbonsäureamide
DE10162375A1 (de) 2001-12-19 2003-07-10 Bayer Ag Bicyclische N-Aryl-amide
CA2475773A1 (en) 2002-02-20 2003-09-04 Pharmacia & Upjohn Company Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
DE10211416A1 (de) 2002-03-15 2003-09-25 Bayer Ag Essig- und Propionsäureamide
DE10211415A1 (de) * 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
DE10234424A1 (de) 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
AU2003250322B2 (en) 2002-08-14 2010-01-21 Neurosearch A/S Novel quinuclidine derivatives and their use
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
MXPA05003317A (es) 2002-09-25 2005-07-05 Memory Pharm Corp Indazoles, benzotiazoles y benzoisotiazoles asi como preparacion y usos de los mismos.
WO2004039321A2 (en) 2002-10-29 2004-05-13 Miicro, Inc. Combinative nicotinic/d1 agonism therapy for the treatment of alzheimer’s disease
WO2004039815A2 (en) 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Compounds having both alpha7 nachr agonist and 5ht antagonist activity for treatment of cns diseases
WO2004039366A1 (en) 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
KR20050085535A (ko) * 2002-12-11 2005-08-29 파마시아 앤드 업존 캄파니 엘엘씨 알파 7 니코틴성 아세틸콜린 수용체 아고니스트와 다른화합물의 조합물을 사용한 질환의 치료 방법
WO2004064836A2 (en) 2003-01-22 2004-08-05 Pharmacia & Upjohn Company Llc Treatment of diseases with alpha-7 nach receptor full agonists
WO2005013910A2 (en) * 2003-08-07 2005-02-17 University Of South Florida Cholinergic modulation of microglial activation via alpha-7 nicotinic receptors
EP1687006B1 (en) 2003-11-18 2007-11-14 Solvay Pharmaceuticals GmbH Pharmaceutical compositions for the treatment of renal dysfunction
GB0329319D0 (en) * 2003-12-18 2004-01-21 Alizyme Therapeutics Ltd Synthesis
US7160876B2 (en) * 2003-12-22 2007-01-09 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20050137398A1 (en) 2003-12-22 2005-06-23 Jianguo Ji 3-Quinuclidinyl heteroatom bridged biaryl derivatives
US20070060588A1 (en) * 2003-12-22 2007-03-15 Jianguo Ji Fused bicycloheterocycle substituted quinuclidine derivatives
US7655657B2 (en) * 2003-12-22 2010-02-02 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20050137204A1 (en) * 2003-12-22 2005-06-23 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
EP1824848A1 (en) 2004-12-10 2007-08-29 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US7241773B2 (en) * 2003-12-22 2007-07-10 Abbott Laboratories 3-quinuclidinyl heteroatom bridged biaryl derivatives
US20050245531A1 (en) * 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20050137203A1 (en) * 2003-12-22 2005-06-23 Jianguo Ji 3-quinuclidinyl amino-substituted biaryl derivatives
WO2005063296A2 (en) * 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders
US7875624B2 (en) 2004-02-20 2011-01-25 Novartis Vaccines And Diagnostics, Inc. Modulating and measuring cellular adhesion
KR20070030196A (ko) * 2004-04-13 2007-03-15 이카겐, 인코포레이티드 칼륨 이온 채널 조절제로서의 폴리시클릭 피리딘
JP2007538046A (ja) 2004-05-19 2007-12-27 ノイロサーチ アクティーゼルスカブ 新規なアザビシクロアリール誘導体
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) * 2004-07-14 2004-08-18 Novartis Ag Organic compounds
EP1802616B1 (en) 2004-10-15 2011-01-12 NeuroSearch A/S Novel azabicyclic aryl derivatives and their medical use
GB0424564D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
ATE481407T1 (de) * 2005-02-16 2010-10-15 Neurosearch As Neue diazabicyclische arylderivate und medizinische verwendung dafür
EP1863485A2 (en) 2005-03-18 2007-12-12 Abbott Laboratories Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions
WO2006113650A1 (en) * 2005-04-18 2006-10-26 Khan Saeed R Design and synthesis of novel tubulin polymerization inhibitors: bonzoylphenyluria (bpu) sulfur analogs
FR2884822B1 (fr) 2005-04-22 2007-06-29 Aventis Pharma Sa Derives de triazines, leur preparation et leur application en therapeutique
GB0508314D0 (en) * 2005-04-25 2005-06-01 Novartis Ag Organic compounds
MX2007016180A (es) * 2005-06-14 2008-03-07 Schering Corp Inhibidores de aspartil proteasas.
GB0521508D0 (en) * 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
TW200813067A (en) 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use

Also Published As

Publication number Publication date
US9475811B2 (en) 2016-10-25
EP2336129A1 (en) 2011-06-22
ES2364971T3 (es) 2011-09-19
US20070249657A1 (en) 2007-10-25
US8933090B2 (en) 2015-01-13
MA28684B1 (fr) 2007-06-01
US20110034475A1 (en) 2011-02-10
PL1761533T3 (pl) 2011-09-30
HK1107559A1 (en) 2008-04-11
CA2566155C (en) 2013-01-08
AU2005254689B2 (en) 2009-09-24
ECSP067053A (es) 2007-01-26
KR20130004383A (ko) 2013-01-09
AU2005254689A1 (en) 2005-12-29
CN1964968A (zh) 2007-05-16
JP4944772B2 (ja) 2012-06-06
NZ551198A (en) 2010-08-27
TNSN06407A1 (en) 2008-02-22
CY1111528T1 (el) 2015-08-05
NO20070339L (no) 2007-03-19
US20150087650A1 (en) 2015-03-26
KR20120047317A (ko) 2012-05-11
ATE506362T1 (de) 2011-05-15
ZA200609255B (en) 2008-07-30
SI1761533T1 (sl) 2011-09-30
PE20060437A1 (es) 2006-06-08
KR101343654B1 (ko) 2013-12-20
KR101174173B1 (ko) 2012-08-14
EP1761533A1 (en) 2007-03-14
EP1761533B1 (en) 2011-04-20
DK1761533T3 (da) 2011-08-08
JP2008502642A (ja) 2008-01-31
WO2005123732A1 (en) 2005-12-29
IL179611A0 (en) 2007-05-15
SG153834A1 (en) 2009-07-29
IL179611A (en) 2013-05-30
DE602005027567D1 (de) 2011-06-01
TW200611904A (en) 2006-04-16
RU2445313C2 (ru) 2012-03-20
PT1761533E (pt) 2011-06-01
IL225968A0 (en) 2013-06-27
MY147262A (en) 2012-11-30
CA2566155A1 (en) 2005-12-29
KR20070032693A (ko) 2007-03-22
AR049401A1 (es) 2006-07-26
MXPA06014697A (es) 2007-02-12
RU2007101653A (ru) 2008-07-27
TWI370128B (en) 2012-08-11
HRP20110535T1 (hr) 2011-08-31
EP1761533B8 (en) 2011-10-12

Similar Documents

Publication Publication Date Title
BRPI0510940A (pt) 1-aza-biciclo-3.1.1-nonanos
BRPI0606644A2 (pt) derivados de 4-carboxamida tiazola
BRPI0910439B8 (pt) derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk), seu processo de preparação, e medicamentos
BR112014026383A2 (pt) derivados de benzamida para inibir a atividade de abl1, abl2 e bcr-abl1
TR200400859T4 (tr) Yeni heterosiklik bileşikler, özellikle antibakteriyel preparatları.
BR112012032234A2 (pt) "derivados de heteroaril imidazolona como inibidores de jak".
BRPI0918750B8 (pt) derivado de 2-carboxamida cicloamino ureia, seu uso e sua composição farmacêutica
BRPI0821653B8 (pt) composto de piridina substituída com anel heterocíclico e grupo fosfonoximetila ou um sal do mesmo, composição farmacêutica compreendendo-os e uso dos mesmos para tratar uma doença fungíca
BR112013001341A2 (pt) compostos de pirimidina como inibidores de proteínas quinases ikk épsilon e/ou tbk-1, processo para a preparação dos mesmos e suas composições farmacêuticas
BRPI0510410A (pt) compostos orgánicos
BRPI0900983B8 (pt) composto de diometina, processo para a síntese do mesmo, composição farmacêutica e seu uso
MA33107B1 (fr) Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
BR112012031406A2 (pt) processo para a preparação de derivados de di-hidropirrol
BRPI0811204A8 (pt) Tetra-hidroibenzo-1,4-diazepinas substituídas por arila e heteroarila e uso das mesmas para bloquear a recaptação de norepinefrina, dopamina e serotonina
BR112012024792A2 (pt) processo de preparo de derivados de sulfonamido-benzofurano
BRPI0511933B8 (pt) derivados de quinazolinona, seu uso e seu processo de preparação, e composição farmacêutica
BRPI0915920A2 (pt) derivados imidazo [1,2-a]pirimidina, o respectivo processo de preparo, a respectiva aplicação a título de medicamentos, composições farmacêuticas e nova utilização notadamente com inibidores de met
BR112022016432A2 (pt) Compostos heterocíclicos de heteroarila e usos dos mesmos
BR112015001207A8 (pt) derivados de carbamato/ureia, seus usos, composição farmacêutica, forma livre e seu método de preparação
BRPI0512677A2 (pt) derivados de quinazolina
BR112012030534A2 (pt) moduladores de receptores 5-ht e métodos de uso dos mesmos
BRPI0406500A (pt) processo farmacêutico e compostos preparados pelo mesmo
EA201000340A1 (ru) Аминобензилзамещенные циклические сульфоны, полезные в качестве ингибиторов васе
BRPI0808570B8 (pt) processo para a preparação de inibidores de glyt-1

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.